Dermata Therapeutics Stock Today
| DRMA Stock | USD 1.10 0.05 4.35% |
Performance0 of 100
| Odds Of DistressOver 85
|
Dermata Therapeutics is trading at 1.10 as of the 28th of November 2024, a 4.35 percent decrease since the beginning of the trading day. The stock's open price was 1.15. Dermata Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Dermata Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of August 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 13th of August 2021 | Category Healthcare | Classification Health Care |
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company was incorporated in 2014 and is headquartered in San Diego, California. The company has 2.04 M outstanding shares of which 93.74 K shares are currently shorted by private and institutional investors with about 0.52 trading days to cover. More on Dermata Therapeutics
Moving together with Dermata Stock
| 0.75 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.75 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.8 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Dermata Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Dermata Stock Highlights
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Jakarta Stock Exchange, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsDermata Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Dermata Therapeutics' financial leverage. It provides some insight into what part of Dermata Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Dermata Therapeutics (DRMA) is traded on NASDAQ Exchange in USA. It is located in 3525 Del Mar Heights Road, San Diego, CA, United States, 92130 and employs 8 people. Dermata Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.25 M. Dermata Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 2.04 M outstanding shares of which 93.74 K shares are currently shorted by private and institutional investors with about 0.52 trading days to cover.
Dermata Therapeutics currently holds about 10.63 M in cash with (6.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.05.
Check Dermata Therapeutics Probability Of Bankruptcy
Ownership AllocationRoughly 98.5 percent of Dermata Therapeutics outstanding shares are held by general public with 0.84 (percent) owned by insiders and only 0.66 % by other corporate entities.
Check Dermata Ownership Details
Dermata Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Tower Research Capital Llc | 2024-06-30 | 1.7 K | |
| Ubs Group Ag | 2024-06-30 | 1.7 K | |
| Wells Fargo & Co | 2024-06-30 | 45.0 | |
| Bank Of America Corp | 2024-06-30 | 3.0 | |
| Acadian Asset Management Llc | 2024-06-30 | 0.0 | |
| Geode Capital Management, Llc | 2024-06-30 | 0.0 | |
| Armistice Capital, Llc | 2024-09-30 | 0.0 | |
| Two Sigma Securities, Llc | 2024-06-30 | 0.0 | |
| Northwestern Mutual Wealth Management Co | 2024-06-30 | 0.0 |
Dermata Therapeutics Historical Income Statement
Dermata Stock Against Markets
Dermata Therapeutics Corporate Management
| Maria MBA | Senior Assurance | Profile | |
| Gerald Proehl | President, Founder | Profile | |
| Sean Proehl | Senior Development | Profile | |
| David Hale | CoFounder Director | Profile | |
| Dr MPH | Senior Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dermata Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dermata Therapeutics. If investors know Dermata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dermata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (13.36) | Return On Assets (0.91) | Return On Equity (1.73) |
The market value of Dermata Therapeutics is measured differently than its book value, which is the value of Dermata that is recorded on the company's balance sheet. Investors also form their own opinion of Dermata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dermata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dermata Therapeutics' market value can be influenced by many factors that don't directly affect Dermata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dermata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dermata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dermata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.